Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Article 2021 en
Authors
MG
Maria Gavriatopoulou
PM
Panagiotis Malandrakis
IN
Ioannis Ntanasis‐Stathopoulos
Abstract
1 min read
The available nonselective proteasome inhibitors have changed the therapeutics of multiple myeloma the last 10 years and have significantly improved the clinical outcomes of the patients. Furthermore, selective proteasome inhibitors are now under preclinical investigation and there is hope that their optimization will come with an improved safety profile with at least comparable efficacy.
Eleni‐Dimitra Papanagnou, Evangelos Terpos, Efstathios Kastritis, Issidora S. Papassideri, Ourania Tsitsilonis, Meletios A Dimopoulos, Ioannis P. Trougakos
Discussion(0)
No comments yet. Be the first to comment.